# US 2021/0330781 A1 · Induce and enhance immune responses using recombinant replicon systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330781 A1
- Document ID: US20210330781A1
- Status: Published application
- Kind: A1
- Application number: 17/369,091
- Filed: 2021-07-07
- Published: 2021-10-28
- Earliest claimed: 2018-01-19
- Assignees: Janssen Pharmaceuticals, Inc.
- Applicants: Janssen Pharmaceuticals, Inc.
- Inventors: Kurt Iver KAMRUD; Nathaniel Stephen WANG; Parinaz ALIAHMAD; Jason L. DEHART
- Web page: https://patentgrep.com/patent/US20210330781A1

## CPC

- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- A61P 31/16: for influenza or rhinoviruses
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20043: viral genome or elements thereof as genetic vector
- C12N 2770/36143: viral genome or elements thereof as genetic vector
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present disclosure generally relates to the use of different self-amplifying RNA molecules to enhance immune responses, for example immune responses following prophylactic vaccination or therapeutic administration. Some embodiments relate to compositions and methods for inducing an immune response in a subject using prime-boost immunization regimens.

## Claims

### Claim 1

A composition comprising:
a priming composition comprising a first RNA replicon which encodes a first antigen; and
a boosting composition comprising a second RNA replicon which encodes a second antigen wherein the first and second RNA replicons are different from each other.

### Claim 2

A composition comprising:
a first nucleic acid sequence encoding a first RNA replicon which encodes a first antigen; and
a second nucleic acid sequence encoding a second RNA replicon which encodes a second antigen,
wherein the first and second RNA replicons are different from each other,
wherein the first replicon and/or the second replicon comprises at least one expression cassettes comprising a promoter operably linked to a coding sequence for a molecule of interest.